SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors rally around the companys pivot from its legacy hardware business to a dominant role in providing the foundational, safety-certified software (QNX) and security infrastructure for robotics and Physical AI. The community is actively discussing the stock's recent bullish momentum and potential for a breakout, driven by anticipation of upcoming earnings and deep-rooted confidence in the company's long-term integration into next-generation autonomous and industrial technology.

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending due to a major partnership with the DTCC to integrate tokenized securities on its network, fueling a massive short squeeze and retail excitement. The community is actively debating the project's long-term institutional potential compared to other assets, with many investors holding for significant multi-year price appreciation.

KAIO provides institutional-grade real-world asset (RWA) tokenization infrastructure that seamlessly connects traditional investment funds with digital capital markets. Through its purpose-built protocol, KAIO enables leading global asset managers to issue and distribute regulated tokenized funds across multiple high-performance blockchain networks — including Ethereum, Sei, Hedera, Solana, Aptos, and others — significantly expanding global access to institutional-quality real-world asset strategies for qualified investors.   By tokenizing feeder structures and shares in flagship funds, KAIO brings onchain access to proven strategies such as the BlackRock ICS US Dollar Liquidity Fund (one of the world’s largest institutional money market funds), the Brevan Howard Master Fund, Hamilton Lane’s Senior Credit Opportunities Fund (SCOPE) via the HL SCOPE Access Fund, and Laser Digital’s Laser Carry Fund (LCF), among others. These tokenized vehicles deliver secure, compliant exposure to money market, macro, private credit, and alternative strategies while unlocking new levels of programmability, composability, and 24/7 liquidity in DeFi environments.

KAIO

KAIO is trending as the community debates its potential as a Real World Asset play, with many focused on accumulation patterns and expectations of a technical reversal. Investors are actively discussing the asset's thin liquidity and whether it can maintain its momentum as it climbs the top gainer lists.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

Pinduoduo is experiencing volatility after reporting mixed third-quarter results, where strong profit beats were overshadowed by management warnings regarding slower revenue growth, increased competition, and long-term uncertainty. Investors remain divided, with the community actively debating whether the current price drop is a long-term value opportunity or a sign of deeper structural challenges in the company's e-commerce ecosystem.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as the community debates potential short squeeze dynamics following a massive surge in failure-to-deliver shares and significant short interest. Investors are simultaneously reacting to progress toward a commercial launch for the company's lead gene-editing therapy and active discussions regarding the impact of recent institutional capital raises.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is currently trending as a leading decentralized perpetual exchange, with active community discussion focused on its significant market share in the derivatives space and ongoing institutional adoption. Traders are closely monitoring the token's price discovery phase alongside heightened speculation about upcoming exchange listings and broader ecosystem integration.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token is capturing attention as investors track its progress in the decentralized AI sector, particularly regarding its recent token supply reductions and burn initiatives. Community sentiment remains split, with some focus on the potential for a rebound as it nears a billion-dollar market cap, while others continue to debate the volatility and impact of daily sell pressure.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is gaining traction as community members highlight its long-term accumulation, strong holder loyalty, and an upcoming ecosystem airdrop. Supporters view the project as a resilient narrative-driven memecoin that differentiates itself through its AirLock supply control mechanism and a persistent, community-led development culture.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the recent double-digit price decline and guidance adjustments are an overreaction to transient headwinds or a fundamental shift in the company's growth trajectory. The community is actively discussing its appeal as a deep-value opportunity for long-term accumulation, with many traders pointing to institutional share buybacks and strong product pipelines as potential catalysts for a recovery.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is attracting significant attention as investors view it as critical infrastructure for the Base ecosystem's autonomous AI agents, with community members actively discussing its role in generating real protocol revenue and providing essential on-chain DeFi utilities. Despite broader market volatility, proponents are highlighting the token's potential for long-term growth and supply-side dynamics, viewing current price action as an accumulation opportunity for those betting on the future of AI-driven finance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare ETFs to Buy as Eli Lily Steps Into Vaccine Market With $4B Bet

 LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker. 

The Silver Tsunami: Healthcare ETFs to Buy Amid Aging US Demographics

 ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care. 

REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief

Equity

The New York Times reported that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes.


Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Trump Slaps 100% Tariffs On Imported Patented Drugs, Sparing Companies That Onshore Or Cut Prices

The new levies apply to patented drugs made in countries with which the U.S. have no tariff deals and by companies that haven’t inked drug pricing deals with the administration.


Trump Administration Prepares Up To 100% Pharma Tariffs On Drugs From Companies That Have Not Struck A Deal Yet: Report

Pharmaceutical companies can avoid these tariffs if they move their manufacturing to the U.S. or are currently negotiating a deal with the Trump administration.

Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move

Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space. 

QURE, SRPT, MRNA Shares Rally On Report Of Vinay Prasad’s FDA Exit

The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary.


TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

Current Price	$91.72
Prev Close	$92.61
Open	$92.39
Dividend Yield	N/A
50-Day Moving Average	$87.58
Beta	N/A
Avg. Volume	99,281.67
PE Ratio	N/A

52-Week High	$93.05
52-Week Low	$64.33
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IHE
iShares U.S. Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest IHE News

IHEiShares U.S. Pharmaceuticals ETF